Wei Zheng

US Patent:

20110195018, Aug 11, 2011

Filed:

Oct 20, 2008

Appl. No.:

13/125045

Inventors:

Marvin C. Gershengorn - Washington DC, US
Susanne Neumann - Bethesda MD, US
Bruce M. Raaka - Rockville MD, US
Craig J. Thomas - Gaithersburg MD, US
James Inglese - Bethesda MD, US
Noel T. Southall - Chevy Chase MD, US
Steven Titus - Elkridge MD, US
Wei Zheng - Potomac MD, US
Wenwei Huang - Rockville MD, US
Gerd Krause - Berlin, DE
Gunnar Kleinau - Brelin, DE

International Classification:

A61K 49/00
C07D 239/88
C07D 217/24
A61K 31/47
A61P 35/00
A61K 31/167
A61K 31/517
C07C 233/01

US Classification:

424 111, 544253, 546141, 564221, 424 91, 51426631, 514309, 514625, 424 189

Abstract:

Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.

US Patent:

20130004490, Jan 3, 2013

Filed:

Dec 14, 2010

Appl. No.:

13/515050

Inventors:

Juan Jose Marugan - Gaithersburg MD, US
Wei Zheng - Potomac MD, US

Assignee:

UNIVERSITY OF MARYLAND, COLLGE PARK - College Park MD
of Health and Human Services - Bethesda MD

International Classification:

A61K 39/395
C07K 16/18
A61K 39/44
C12N 15/62
A61P 25/28
C12N 1/21
C08G 63/91
C12P 21/02
C12N 15/63
C12N 1/19
C12N 5/10
A61K 38/17
C07K 19/00

US Classification:

4241341, 514 135, 5303873, 4241361, 536 234, 530380, 525 541, 4241791, 5303911, 435 697, 4353201, 4352542, 435419, 435325, 435348, 435365, 435358, 435369, 43525233

Abstract:

The invention provides a composition comprising transthyretin and an ICAM-1 targeting agent, wherein the transthyretin and ICAM-1 targeting agent are coupled together, as well as methods of preparing such compositions. The invention further provides a diabody capable of binding specifically to ICAM-1 and transthyretin. The invention also provides a method of use of such composition in the manufacture of a medicament for treating an amyloid-β related neurodegenerative disease, comprising administering to a subject a composition comprising transthyretin coupled to an ICAM-1 targeting agent in an amount effective to treat the neurodegenerative disease, wherein the composition is administered to the subject outside of the blood-brain barrier.

US Patent:

20130096160, Apr 18, 2013

Filed:

Apr 14, 2011

Appl. No.:

13/641383

Inventors:

Juan Jose Marugan - Gaithersburg MD, US
Jingbo Xiao - Rockville MD, US
Steven A. Titus - Elkridge MD, US
Noel Southall - Chevy Chase MD, US
Wei Zheng - Potomac MD, US
Elliot J. Androphy - Natick MA, US
Jonathan Cherry - Worcester MA, US

Assignee:

Secretary, Department of Health and Human Services - Bethesda MD

International Classification:

C07D 417/04

US Classification:

514326, 546209

Abstract:

Aryl substituted thiazol-2-yl-piperidines and related compounds useful as modulators of survival motor neuron (SMN) protein production are provided herein. Without being bound to any particular theory it is believed the aryl substituted thiazol-2-yl-piperidines and related compounds provided herein act to increase production of the SMN2 form of survival motor neuron protein. These compounds are useful for treating spinal muscular atrophy. Pharmaceutical compositions containing a carrier and one or more of the aryl substituted thiazol-2-yl-piperidine or related compounds described herein are also provided. Methods of treating spinal muscular atrophy are also provided by this disclosure.

US Patent:

20130123214, May 16, 2013

Filed:

Jul 19, 2011

Appl. No.:

13/810774

Inventors:

Wei Zheng - Potomac MD, US
Juan Jose Marugan - Gaithersburg MD, US
Ke Liu - Cambridge MD, US
Noel Terrence Southall - Chevy Chase MD, US
Christopher P. Austin - Potomac MD, US

Assignee:

The United States of America as Represented by the Secretary Department of HR - Rockville MD

International Classification:

A61K 31/355
A61K 31/724
A61K 45/06

US Classification:

514 58, 514458

Abstract:

This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol in combination with cyclodextrin to a patient in need thereof.

US Patent:

20130251631, Sep 26, 2013

Filed:

May 17, 2013

Appl. No.:

13/897330

Inventors:

- Berlin-Adlershof, DE
Bruce M. Raaka - Rockville MD, US
Craig J. Thomas - Gaithersburg MD, US
James Inglese - Bethesda MD, US
Noel T. Southall - Chevy Chase MD, US
Steven Titus - Elkridge MD, US
Wei Zheng - Potomac MD, US
Wenwei Huang - Rockville MD, US
Gerd Krause - Berlin, DE
Gunnar Kleinau - Berlin, DE

Assignee:

Forschungsverbund Berlin E.V. - Berlin-Adlershof
The Government of the United States of America as represented by the Secretary of the Department of - Rockville MD

International Classification:

C07D 405/06
A61K 51/00
A61K 31/517

US Classification:

424 161, 544289, 424 91, 51426624

Abstract:

Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.

US Patent:

20140004082, Jan 2, 2014

Filed:

Mar 15, 2012

Appl. No.:

14/005534

Inventors:

Pu Liu - Bethesda MD, US
Wei Zheng - Potomac MD, US
Juan Marugan - Gaithersburg MD, US
Noel T. Southall - Chevy Chase MD, US
Lea Cunningham - Washington DC, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Services - Bethesda MD

International Classification:

A61K 31/5513
A61K 45/06
A61K 31/40

US Classification:

424 852, 514221, 514423, 514 49, 514 34, 514400, 4241781, 514 46

Abstract:

A method for treating core binding factor (CBF) leukemia in a subject, comprising administering to a subject having CBF leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits CBFβ and RUNX1 binding in the subject, thereby treating the CBF leukemia.

US Patent:

20230000869, Jan 5, 2023

Filed:

Jun 7, 2021

Appl. No.:

17/340589

Inventors:

- Boston MA, US
- Bethesda MD, US
Philip Edward Sanderson - Bethesda MD, US
Jian-Kang Jiang - Columbia MD, US
Khalida Shamim - Gaithersburg MD, US
Wei Zheng - Potomac MD, US
Xiuli Huang - Potomac MD, US
Gregory Tawa - Doylestown PA, US
Arthur Lee - San Jose CA, US
Asaf Alimardanov - North Bethesda MD, US
Junfeng Huang - Woodstock MD, US

International Classification:

A61K 31/519
A61P 19/08
A61K 31/5377
A61K 31/551
A61K 31/675
A61K 45/06
C07D 487/04
C07D 519/00
C07F 9/6561

Abstract:

The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

US Patent:

20210246137, Aug 12, 2021

Filed:

Apr 22, 2021

Appl. No.:

17/237351

Inventors:

- Bethesda MD, US
- Chicago IL, US
Wei Sun - Germantown MD, US
Xiuli Huang - Potomac MD, US
Paresma R. Patel - Rockville MD, US
Wei Zheng - Potomac MD, US
Xiao Lu - Rockville MD, US
Philip E. Sanderson - Bethesda MD, US
Myunghoon Kim - Olympia WA, US
Meghan J. Orr - Nashville IL, US
Gregory J. Tawa - Doylestown PA, US
Kim C. Williamson - Bethesda MD, US

Assignee:

The United States of America,as represented by the Secretary,Department of Health and Human Services - Bethesda MD
Loyola University of Chicago - Chicago IL

International Classification:

C07D 471/04
A61P 33/06
C07D 487/04
C07D 487/08
C07D 519/00

Abstract:

Disclosed are compounds of formula (I) and formula (II):wherein R, R, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.